Search details
1.
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Blood
; 119(24): 5661-70, 2012 Jun 14.
Article
in English
| MEDLINE | ID: mdl-22555973
2.
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Blood
; 118(3): 535-43, 2011 Jul 21.
Article
in English
| MEDLINE | ID: mdl-21596852
Results
1 -
2
de 2
1
Next >
>>